Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Year: 2006
Type: article
Study design: Clinical Trial
Source: PubMed
Authors: David A Reardon, Jennifer A Quinn, Gamal Akabani, R Edward Coleman, Allan H Friedman, Henry S Friedman, James E Herndon, Roger E McLendon, Charles N Pegram, James M Provenzale, Jeannette M Dowell, Jeremy N Rich, James J Vredenburgh, Annick Desjardins, John H Sampson, Sridharan Gururangan, Terence Z Wong, Michael A Badruddoja, Xiao-Guang Zhao, Darell D Bigner, Michael R Zalutsky
Institutions: Duke University, Duke Medical Center
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W2187658107